Early detection of Diabetic Autonomic Neuropathy

MJ. Lafitte* M. Fèvre-Genoulaz* SS. Srikanta*
L. Punitha* S. Vidyanand*

DyAnsys, Inc., USA

Background and Aim: Diabetic patients are at high risk of developing diabetic autonomic neuropathy (DAN). The aim of this study was to compare autonomic scoring and measurements from a new device, the ANSiscope™, made on patients with type 2 diabetes.

Methods: After approval from the ethics committee, 18 type-2 diabetic patients (mean age 48±7.5 years) without any complication due to DAN were included in the study. They all underwent 2 types of autonomic neuropathy assessment:

- Autonomic dysfunction measurement with the ANSiscope™ (see photograph):
The device computes a percentage of dysautonomia from a recording of 572 RR intervals (between 5 and 7 minutes) of a patient at rest in supine position.
Patients are classified as having healthy (H)/early(E)/late(L)/advanced(A) or most advanced (MA) dysautonomia.

- Autonomic scoring:
3 standard autonomic tests were performed: Valsalva manoeuvre, respiratory sinus arrhythmia, ratio 30:15 and blood pressure fall after tilt test. Classification between healthy(H)/early(E) and advanced(A) was deduced from scoring described by Bellavere et al. Resting heart rate was used to confirm parasympathetic dysfunction in patients with most advanced DAN.

Results:

Discussion: Autonomic scoring was only able to detect 2 groups of patients: 13 H and 5 E whereas the ANSiscope™ detected 5 groups: 2H, 3E, 4L, 7A and 2MA. The results obtained by the ANSiscope™ were stable and reproducible. The 2 MA cases had a resting heart rate > 100, which confirms parasympathetic dysfunction. These cases were classified as healthy by autonomic scoring. Conclusion: When no complication indicates a dysfunction of autonomic nervous system and autonomic scoring detects only early stage of DAN, the ANSiscope™ was able to classify the patients in a reproducible manner. This device may be a useful tool to assess DAN in patients without clinical complications and help stratify patients at high risk to develop these symptoms. Furthermore, the time required for one measurement (i.e. around 5 minutes) makes it a valuable device for clinical practice.

ANSiscope Autonomic Scoring

ANSSiscope is a registered trademark of DyAnsys, Inc.

*Corresponding authors.